PortalPublikationenMembranöse Glomerulonephritis

Membranöse Glomerulonephritis

Standard

Membranöse Glomerulonephritis : Differenziertere Therapien durch Autoantikörperbestimmung? / Stahl, R A; Hoxha, E; Helmchen, U.

in: DEUT MED WOCHENSCHR, Jahrgang 136, Nr. 34-35, 08.2011, S. 1733-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stahl, RA, Hoxha, E & Helmchen, U 2011, 'Membranöse Glomerulonephritis: Differenziertere Therapien durch Autoantikörperbestimmung?', DEUT MED WOCHENSCHR, Jg. 136, Nr. 34-35, S. 1733-7. https://doi.org/10.1055/s-0031-1286067

APA

Stahl, R. A., Hoxha, E., & Helmchen, U. (2011). Membranöse Glomerulonephritis: Differenziertere Therapien durch Autoantikörperbestimmung? DEUT MED WOCHENSCHR, 136(34-35), 1733-7. https://doi.org/10.1055/s-0031-1286067

Vancouver

Stahl RA, Hoxha E, Helmchen U. Membranöse Glomerulonephritis: Differenziertere Therapien durch Autoantikörperbestimmung? DEUT MED WOCHENSCHR. 2011 Aug;136(34-35):1733-7. https://doi.org/10.1055/s-0031-1286067

Bibtex

@article{239a884149194c039c09430f894f794d,
title = "Membran{\"o}se Glomerulonephritis: Differenziertere Therapien durch Autoantik{\"o}rperbestimmung?",
abstract = "Membranous nephropathy is the most common cause of nephrotic syndrome in adults. Binding of circulating autoantibodies to the glomerular filtration barrier leads to the development of this autoimmune disease. The clinical symptoms range from small proteinuria to severe nephrotic syndrome with enormous oedema, not controllable hyperlipidaemia and increased disposition for infection. One third of patients reach complete or partial remission of proteinuria under symptomatic treatment, which includes ACE-inhibitors and AT-I-blockers, loop diuretics and statins. Untreated the disease leads to loss of renal function over 5-10 years in 20-30% of patients. A risk score based on proteinuria and renal function is used to guide the decision when to start with an immunosuppressive therapy. A better adapted diagnostic and therapy of membranous nephropathy may be possible through measurement of circulating autoantibodies directed against a podocytic phospholipase-A(2) receptor.",
keywords = "Antibodies, Monoclonal, Murine-Derived, Autoantibodies, Biopsy, Diagnosis, Differential, Follow-Up Studies, Glomerulonephritis, Membranous, Humans, Immunologic Factors, Immunomodulation, Immunosuppressive Agents, Kidney Glomerulus, Male, Middle Aged, Nephrotic Syndrome, Prognosis, Receptors, Phospholipase A2, Rituximab, Case Reports, English Abstract, Journal Article, Review",
author = "Stahl, {R A} and E Hoxha and U Helmchen",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2011",
month = aug,
doi = "10.1055/s-0031-1286067",
language = "Deutsch",
volume = "136",
pages = "1733--7",
journal = "DEUT MED WOCHENSCHR",
issn = "0012-0472",
publisher = "Georg Thieme Verlag KG",
number = "34-35",

}

RIS

TY - JOUR

T1 - Membranöse Glomerulonephritis

T2 - Differenziertere Therapien durch Autoantikörperbestimmung?

AU - Stahl, R A

AU - Hoxha, E

AU - Helmchen, U

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2011/8

Y1 - 2011/8

N2 - Membranous nephropathy is the most common cause of nephrotic syndrome in adults. Binding of circulating autoantibodies to the glomerular filtration barrier leads to the development of this autoimmune disease. The clinical symptoms range from small proteinuria to severe nephrotic syndrome with enormous oedema, not controllable hyperlipidaemia and increased disposition for infection. One third of patients reach complete or partial remission of proteinuria under symptomatic treatment, which includes ACE-inhibitors and AT-I-blockers, loop diuretics and statins. Untreated the disease leads to loss of renal function over 5-10 years in 20-30% of patients. A risk score based on proteinuria and renal function is used to guide the decision when to start with an immunosuppressive therapy. A better adapted diagnostic and therapy of membranous nephropathy may be possible through measurement of circulating autoantibodies directed against a podocytic phospholipase-A(2) receptor.

AB - Membranous nephropathy is the most common cause of nephrotic syndrome in adults. Binding of circulating autoantibodies to the glomerular filtration barrier leads to the development of this autoimmune disease. The clinical symptoms range from small proteinuria to severe nephrotic syndrome with enormous oedema, not controllable hyperlipidaemia and increased disposition for infection. One third of patients reach complete or partial remission of proteinuria under symptomatic treatment, which includes ACE-inhibitors and AT-I-blockers, loop diuretics and statins. Untreated the disease leads to loss of renal function over 5-10 years in 20-30% of patients. A risk score based on proteinuria and renal function is used to guide the decision when to start with an immunosuppressive therapy. A better adapted diagnostic and therapy of membranous nephropathy may be possible through measurement of circulating autoantibodies directed against a podocytic phospholipase-A(2) receptor.

KW - Antibodies, Monoclonal, Murine-Derived

KW - Autoantibodies

KW - Biopsy

KW - Diagnosis, Differential

KW - Follow-Up Studies

KW - Glomerulonephritis, Membranous

KW - Humans

KW - Immunologic Factors

KW - Immunomodulation

KW - Immunosuppressive Agents

KW - Kidney Glomerulus

KW - Male

KW - Middle Aged

KW - Nephrotic Syndrome

KW - Prognosis

KW - Receptors, Phospholipase A2

KW - Rituximab

KW - Case Reports

KW - English Abstract

KW - Journal Article

KW - Review

U2 - 10.1055/s-0031-1286067

DO - 10.1055/s-0031-1286067

M3 - SCORING: Zeitschriftenaufsatz

C2 - 21877306

VL - 136

SP - 1733

EP - 1737

JO - DEUT MED WOCHENSCHR

JF - DEUT MED WOCHENSCHR

SN - 0012-0472

IS - 34-35

ER -